This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $30,739.63 firm fixed-price contract is for the delivery of Vyvanse capsules, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract is not set aside and has an ultimate completion date of April 18, 2025. AmerisourceBergen Drug Corp holds a larger $999,999,999.00 Indefinite Delivery...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,783.60, is for the delivery of Vyvanse 10 mg capsules, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract is a firm-fixed-price contract with an ultimate completion date of January 2, 2025. This contract is part of a larger Indefinite Delivery...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Vyvanse capsules, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract has a ceiling value of $29,021.99 and a period of performance through April 28, 2025. This order is part of a larger Indefinite Delivery Contract (IDC) with DLA Troop...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Vyvanse 60 mg capsules, a medication used to treat Attention Deficit Hyperactivity Disorder (ADHD). The contract has a firm fixed price of $4,515.51 and a completion date of May 13, 2025. The contract is not set aside for a specific business type. AmerisourceBergen Drug...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has a ceiling value of $38,477.28 and covers the delivery of Vyvanse (lisdexamfetamine dimesylate) 30mg capsules, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract is a firm fixed-price, non-set-aside award with a period of performance through April 30, 2025....
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Vyvanse 10 mg capsules, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract is a firm-fixed-price, non-set-aside contract with a ceiling value of $1,854.50 and a period of performance through April 16, 2025. AmerisourceBergen Drug Corp holds a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,638.64 firm fixed-price delivery order is for the supply of Vyvanse 10 mg capsules, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract has an ultimate completion date of November 4, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC)...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $5,751.46, is for the supply of Vyvanse 40 mg capsules, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract is a firm-fixed-price delivery order, with a completion date of February 21, 2025. AmerisourceBergen holds a larger Indefinite Delivery Contract...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $27,518.18 firm-fixed-price contract is for the delivery of 4,568,169,968 units of Vyvanse 40mg capsules, a prescription medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract has an ultimate completion date of May 8, 2025 and is not designated as a set-aside. AmerisourceBergen Drug Corp holds a $999,999,999.00...
This federal contract award, valued at $4,401.60, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of Vyvanse 30 mg capsules, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract is a Firm Fixed Price Delivery Order, with an ultimate completion date of April 18, 2025. This contract is not set aside for any specific business type. AmerisourceBergen Drug Corp...